NASDAQ : SCNX

Scienture Holdings, Inc. — Company profile

Healthcare · Pharmaceutical Retailers · United States

Last price 3.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Details

NameScienture Holdings, Inc.
SectorHealthcare
IndustryPharmaceutical Retailers
Employees9
Founded2010
Ipo Date2020-02-13
CeoShankar Hariharan
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS80880X2036
Cusip80880X203
Cik1382574
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Narasimhan Mani M.B.A., Ph.D.President, Co-Chief Executive Officer, Interim Chief Financial Officer and Director
Dr. Shankar Hariharan Ph.D.Founder, Co-Chief Executive Officer and Executive Chairman
Rahul Surana M.B.A., Ph.D.Executive Vice President and Chief Operating Officer of Scienture LLC
Michele RathSenior Vice President and Chief Commercial Officer of Scienture LLC

Contact

Address20 Austin Boulevard, Commack, New York 11725, United States
Phone631 670 6039
Websitehttps://scienture.com